Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases
Drug Design, Development and Therapy · 2023-07 · Volume 17 · 1963-1978
DOI: 10.2147/dddt.s416091 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2023-07. Verfasst von Junlan Tan und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People's Republic of China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Saponins, Triterpenes, Respiratory Tract Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Respiratory diseases are an emerging public health concern, that pose a risk to the global community. There, it is essential to establish effective treatments to reduce the global burden of respiratory diseases. Astragaloside IV (AS-IV) is a natural saponin isolated from Radix astragali (Huangqi in Chinese) used for thousands of years in Chinese medicine. This compound has become increasingly popular due to its potential anti-inflammatory, antioxidant, and anticancer properties. In the last decade, accumulated evidence has indicated the AS-IV protective effect against respiratory diseases. This article presents a current understanding of AS-IV roles and mechanisms in combatting respiratory diseases. The ability of the agent to suppress oxidative stress, cell proliferation, and epithelial-mesenchymal transition (EMT), to attenuate inflammatory responses, and modulate programmed cell death (PCD) will be discussed. This review highlights the current challenges in respiratory diseases and recommendations to improve disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People's Republic of China.
- Hunan Provincial Key Laboratory of Vascular Biology and Translational Medicine, Changsha, Hunan, 410208, People's Republic of China.
- The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410021, People's Republic of China.
- Department of Respiratory Diseases, School of Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People's Republic of China.
- Department of Respiratory Medicine, the First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410021, People's Republic of China.
Zitieren
APA
Tan, J., Yi, J., Cao, X., Wang, F., Xie, S., & Dai, A. (2023). Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases. Drug Design, Development and Therapy, Volume 17, 1963-1978. https://doi.org/10.2147/dddt.s416091
Vancouver
Tan J, Yi J, Cao X, Wang F, Xie S, Dai A. Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases. Drug Design, Development and Therapy. 2023;Volume 17:1963-1978. doi:10.2147/dddt.s416091
BibTeX
@article{Tan2023,
author = {Tan, Junlan and Yi, Jian and Cao, Xianya and Wang, Feiying and Xie, Silin and Dai, Aiguo},
title = {Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases},
journal = {Drug Design, Development and Therapy},
year = {2023},
volume = {Volume 17},
pages = {1963--1978},
doi = {10.2147/dddt.s416091}
}
EUVIMED